Physician profile
Mary Yursky
NPI 1144246570
$7,694.22
in general payments reported to CMS, 2019-2025
22 companies · $1,632 in 2025
The $1,632 reported for 2025 was more than what 92% of Gastroenterology (Registered Nurse) providers received nationally (typical 2025 total: $239).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $642 · 2022: $966 · 2023: $3,950 · 2024: $505 · 2025: $1,632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,087 · Consulting Fee: $3,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,086.65 |
| Consulting Fee | $3,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,311.12 | 2022-2024 | Stelara, Tremfya, Simponi |
| Abbvie INC. | $2,194.35 | 2021-2025 | |
| Pfizer INC. | $362.14 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $330.60 | 2021-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $150.58 | 2021-2025 | Xifaxan |
| Celgene Corporation | $147.18 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $125.00 | 2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $124.88 | 2022-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $122.60 | 2021-2024 | Dificid, Zinplava |
| Genzyme Corporation | $112.08 | 2022-2025 | |
| Lilly USA, LLC | $107.48 | 2024-2025 | Omvoh |
| Braintree Laboratories, INC. | $101.56 | 2021-2025 | Sutab, Suflave |
| E.R. Squibb & Sons, L.L.C. | $99.00 | 2021 | |
| Ardelyx, INC. | $83.38 | 2022-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $82.88 | 2021-2024 | Linzess |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $55.89 | 2023-2025 | Vowst |
| Qol Medical, LLC | $54.74 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $53.65 | 2021-2023 | |
| Ferring Pharmaceuticals INC. | $35.40 | 2025 | Rebyota |
| Madrigal Pharmaceuticals | $14.12 | 2025 | Rezdiffra |
| Celltrion USA INC. | $14.03 | 2025 | Vegzelma |
| Organon LLC | $11.56 | 2025 | Renflexis, Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Yursky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.